Opportunity Information: Apply for PAR 14 257
Apply for PAR 14 257
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Jun 10, 2014 and posted on Jun 10, 2014.
- Applicants must submit their applications by Nov 20, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $4,000,000.00 in funding.
- Eligible applicants include: County governments City or township governments Independent school districts Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education State governments Special district governments Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 14-257, titled "Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3)," supports ancillary research projects that make new scientific use of already-collected, archived biospecimens from specific completed or ongoing type 1 diabetes clinical trials and related studies. The central idea is to unlock additional value from these carefully curated sample collections by allowing investigators to ask new questions that were not part of the original trial aims, without having to launch an entirely new, expensive sample-collection effort. Projects are expected to be designed around the use of these stored samples and to take advantage of the rich clinical and outcome data linked to the parent studies.
The scientific focus is on advancing understanding of type 1 diabetes biology and outcomes in a way that can plausibly inform future prevention or treatment strategies. Proposed ancillary studies are expected to generate discoveries in areas such as the primary pathogenesis of type 1 diabetes (how the disease starts and progresses), the pathogenesis of complications (mechanisms driving complications over time), and the identification or validation of biomarkers. The FOA emphasizes biomarkers that help track disease progression or predict and measure clinical responses to interventions, which can be especially valuable for improving trial design, patient stratification, and monitoring treatment effects. In practice, this could include molecular, immunologic, genetic, proteomic, metabolomic, or other laboratory analyses performed on archived specimens, with the goal of connecting biological signals to well-characterized clinical trajectories and trial outcomes.
This announcement uses the DP3 grant mechanism, which is commonly associated with high-impact, discovery-oriented, and often collaborative projects that leverage existing resources. While the summary information provided does not spell out all administrative details of the DP3 structure, the headline intent is clear: to fund targeted, hypothesis-driven (or strongly discovery-driven) analyses that can produce meaningful insights relatively efficiently because the biosamples and associated clinical context already exist.
The opportunity is categorized as a discretionary grant within the NIH’s health-related research portfolio and is associated with CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), reflecting its alignment with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) mission area. There is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of receiving an award.
In terms of who can apply, eligibility is broad and includes many types of domestic U.S. organizations as well as non-U.S. entities. Eligible applicants span state and local governments, tribal governments and tribal organizations, public housing authorities, independent school districts, special district governments, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), public and private institutions of higher education, and for-profit organizations (other than small businesses), as well as small businesses. The eligibility language also explicitly includes a wide range of institution types and communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations. Non-domestic (foreign) organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies are also listed as eligible.
Key dates indicate that the FOA was posted and created on June 10, 2014, with an original and current closing date of November 20, 2014, and an archive date of December 21, 2014. The award ceiling is listed as $4,000,000, signaling that NIH anticipated some projects could be large in scope and budget, likely reflecting the costs of complex assays, multi-site collaboration, extensive statistical analysis, and rigorous validation work often needed for biomarker or mechanistic studies using clinical-trial biospecimens.
For applicants needing the full technical and administrative requirements, NIH provided an official announcement link hosted on the NIH grants guide, and points of contact through the NIH Office of Extramural Research (OER) webmaster for access or linking issues. Overall, this FOA is best understood as a targeted opportunity to accelerate type 1 diabetes discovery by pairing high-quality archived clinical-trial samples with modern analytical approaches, aiming to produce mechanistic insights and practical biomarkers that can shape future research and clinical care.
Frequently Asked Questions (FAQs)
What is PAR 14-257?
PAR 14-257 is an NIH funding opportunity announcement titled "Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3)." It supports ancillary research projects that use already-collected, archived biospecimens from specific completed or ongoing type 1 diabetes clinical trials and related studies.
What is the main purpose of this funding opportunity?
The purpose is to unlock additional scientific value from curated collections of stored biospecimens by enabling investigators to ask new research questions that were not part of the original clinical trial aims, without having to start a new and costly sample-collection effort.
What kind of research does the FOA support?
The FOA supports ancillary studies designed around the use of stored (archived) biosamples linked to rich clinical and outcome data from the parent type 1 diabetes clinical studies.
What does "ancillary research" mean in this context?
Here, "ancillary research" refers to new analyses conducted using biospecimens that were collected as part of existing type 1 diabetes clinical trials or related studies. The ancillary work is intended to address questions beyond the original goals of the parent study.
What types of biospecimens are expected to be used?
The announcement focuses on already-collected, archived biospecimens from selected type 1 diabetes clinical studies. The specific biospecimen types are not listed in the provided summary, but the intent is that the project is built around stored samples from the eligible parent trials/studies.
Do projects need to collect new samples?
The central emphasis is on using already-collected, archived biospecimens, rather than launching a new biospecimen collection effort. Projects are expected to be designed around the use of stored samples.
What scientific areas are emphasized?
The FOA emphasizes research that advances understanding of type 1 diabetes biology and outcomes, with the potential to inform future prevention or treatment strategies. Highlighted areas include:
- Primary pathogenesis of type 1 diabetes (how the disease starts and progresses)
- Pathogenesis of complications (mechanisms driving complications over time)
- Identification or validation of biomarkers
What kinds of biomarkers are of interest?
The FOA emphasizes biomarkers that can help track disease progression or predict and measure clinical responses to interventions. These biomarkers are positioned as useful for improving future trial design, patient stratification, and monitoring treatment effects.
What kinds of laboratory analyses might be proposed?
The summary describes analyses such as molecular, immunologic, genetic, proteomic, metabolomic, or other laboratory approaches performed on archived specimens, with the goal of linking biological signals to clinical trajectories and trial outcomes.
How does linked clinical data factor into the research?
Projects are expected to take advantage of the rich clinical and outcome data associated with the parent clinical trials and related studies, connecting biospecimen-derived findings to well-characterized clinical trajectories and trial results.
What grant mechanism is used for this opportunity?
This announcement uses the DP3 grant mechanism, described in the summary as commonly associated with high-impact, discovery-oriented, and often collaborative projects that leverage existing resources.
Is the research expected to be hypothesis-driven, discovery-driven, or both?
The summary indicates that projects may be hypothesis-driven or strongly discovery-driven, as long as they are targeted analyses using archived biospecimens and can produce meaningful insights efficiently due to the existing sample collections and clinical context.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.847, described as "Diabetes, Digestive, and Kidney Diseases Extramural Research," reflecting alignment with the NIDDK mission area.
Is this a discretionary grant?
Yes. The opportunity is categorized as a discretionary grant within NIH's health-related research portfolio.
Is cost sharing or matching required?
No. The summary states there is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of receiving an award.
Who is eligible to apply?
Eligibility is broad and includes many domestic U.S. organizations and non-U.S. entities. Eligible applicants listed in the summary include:
- State and local governments
- Tribal governments and tribal organizations
- Public housing authorities
- Independent school districts
- Special district governments
- Nonprofit organizations (501(c)(3) and non-501(c)(3))
- Public and private institutions of higher education
- For-profit organizations (other than small businesses)
- Small businesses
- Non-domestic (foreign) organizations
- Regional organizations
- U.S. territories or possessions
- Eligible federal agencies
Are minority-serving institutions specifically included as eligible applicants?
Yes. The eligibility language explicitly includes a wide range of institution types and communities, including HBCUs, Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly included in the eligibility description.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The summary explicitly lists non-domestic (foreign) organizations among eligible applicants.
What is the award ceiling for this opportunity?
The award ceiling is listed as $4,000,000, suggesting NIH anticipated that some projects could be large in scope and budget.
Why might budgets be large for projects under this FOA?
The summary suggests the ceiling may reflect the costs of complex assays, multi-site collaboration, extensive statistical analysis, and rigorous validation work often needed for biomarker or mechanistic studies using clinical-trial biospecimens.
When was this FOA posted and when did it close?
Key dates in the summary indicate the FOA was posted/created on June 10, 2014, had an original and current closing date of November 20, 2014, and an archive date of December 21, 2014.
Is this funding opportunity still open?
Based on the provided dates (closing date November 20, 2014, archive date December 21, 2014), this FOA is presented as closed and archived.
Where can applicants find the official announcement details?
The summary notes that NIH provided an official announcement link hosted on the NIH grants guide for full technical and administrative requirements.
Who is listed as a point of contact for access or linking issues?
The summary references points of contact through the NIH Office of Extramural Research (OER) webmaster for access or linking issues related to the official announcement.
What is the overall intended impact of this FOA?
The FOA is intended to accelerate type 1 diabetes discovery by pairing high-quality archived clinical-trial samples with modern analytical approaches, aiming to produce mechanistic insights and practical biomarkers that can shape future research and clinical care.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: National Park Service Adaptive Restoration and Community Stewardship Project
Previous opportunity: Research Supplements for Aging Research on Health Disparities (Admin Supp)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 257
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 257) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 258 Funding Number: PAR 14 258 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $7,000,000 |
| Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) (U01) Apply for RFA DK 14 011 Funding Number: RFA DK 14 011 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
| Improving Diabetes Management in Young Children with Type 1 Diabetes (DP3) Apply for RFA DK 14 022 Funding Number: RFA DK 14 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Critical Path Public Private Partnerships Apply for RFA FD 14 089 Funding Number: RFA FD 14 089 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $10,500,000 |
| NIDDK Mentored Research Scientist Development Award (K01) Apply for PAR 14 266 Funding Number: PAR 14 266 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Data Coordinating Center for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4) Apply for RFA DK 14 505 Funding Number: RFA DK 14 505 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $20,000,000 |
| NIAID SBIR Technology Transfer Direct Phase II (SBIR TT) (R44) Apply for RFA AI 14 049 Funding Number: RFA AI 14 049 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| NIDDK Cooperative Hematology Specialized Core Centers (U54) Apply for RFA DK 14 001 Funding Number: RFA DK 14 001 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| Limited Competition for the Continuation of the Adult Acute Liver Failure Study Group (U01) Apply for RFA DK 14 504 Funding Number: RFA DK 14 504 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $3,500,000 |
| NIDDK Physician Scientist Diversity Mentoring Award (K05) Apply for RFA DK 14 005 Funding Number: RFA DK 14 005 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| NIDDK Central Repositories Non renewable Sample Access (X01) Apply for PAR 14 301 Funding Number: PAR 14 301 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Centers (U01) Apply for RFA DK 14 016 Funding Number: RFA DK 14 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
| Prevention of Lower Urinary Tract Symptoms in Women Bladder Health Scientific and Data Coordinating Center (PLUS SDCC) (U01) Apply for RFA DK 14 018 Funding Number: RFA DK 14 018 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Prevention of Lower Urinary Tract Symptoms in Women Bladder Health Clinical Centers (PLUS CCs) (U01) Apply for RFA DK 14 004 Funding Number: RFA DK 14 004 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Limited Competition Data Coordinating Center for Type 1 Diabetes TrialNet (UC4) Apply for RFA DK 14 507 Funding Number: RFA DK 14 507 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $45,000,000 |
| Identification of Novel Targets and Pathways Mediating Weight Loss, Diabetes Resolution and Related Metabolic Disease after Bariatric Surgery in Humans (R01) Apply for RFA DK 14 025 Funding Number: RFA DK 14 025 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Limited Competition for the Continuation of the Hepatitis B Research Network Clinical Centers (U01) Apply for RFA DK 14 506 Funding Number: RFA DK 14 506 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Hepatitis B Research Network Immunology Center (U01) Apply for RFA DK 14 509 Funding Number: RFA DK 14 509 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Hepatitis B Research Network Data Coordination Center (U01) Apply for RFA DK 14 510 Funding Number: RFA DK 14 510 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Type 1 Diabetes Complications IMPACT Award (DP3) Apply for RFA DK 14 017 Funding Number: RFA DK 14 017 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 257", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.